Date: 2018-12-17

Type of information: Collaboration agreement

Compound: Parkinson’s Disease Education Consortium, Parkinson’s Progression Markers Initiative

Company: Voyager Therapeutics (USA-MA) The Michael J. Fox Foundation for Parkinson’s Research (MJFF) (USA)

Therapeutic area: Neurological diseases - Neurodegenerative diseases

Type agreement: collaboration

Action mechanism:

Disease: Parkinson's disease

Details: • On December 17, 2018, Voyager Therapeutics announced joining multiple partnerships with The Michael J. Fox Foundation for Parkinson’s Research (MJFF) including the Parkinson’s Progression Markers Initiative (PPMI) and the Parkinson’s Disease Education Consortium (PDEC). PPMI is a landmark natural history study launched in 2010 to help identify, develop, and validate biomarkers of Parkinson’s disease progression to further the development of disease-modifying therapies. PPMI is funded by MJFF and a consortium of key industry players, non-profit organizations, and private individuals and involves active participation of stakeholders from government, the biopharmaceutical industry, and academia to collectively design, implement and fund this comprehensive program. With involvement from more than 30 clinical sites in 11 countries and more than 1,000 participants, PPMI collects and examines clinical and biologic measures to track disease progression in early-stage Parkinson’s and prodromal patients and certain genetic populations for use in clinical trials of disease-modifying therapies. Voyager representatives will join PPMI’s Industry Scientific Advisory Board, which serves as an independent forum for all PPMI industry partners and is closely involved in the design and execution of the project. Launched in 2016, PDEC is an alliance between MJFF and industry partners committed to patient and caregiver knowledge. PDEC supports the development of MJFF’s evergreen educational programs (e.g., Third Thursdays Webinar series) and spotlights annual campaigns focused on addressing unmet needs in Parkinson’s community education. Past campaigns have included a narrative on the Parkinson’s disease patient journey, a companion pack for clinical trial volunteers, and study teams to address research participation, and a research initiative aimed at addressing barriers to communication between patients, care-givers and healthcare practitioners. In 2019 and 2020, MJFF, in partnership with PDEC, will lead an effort to bring education to people with Parkinson’s, supporters, and caregivers through local community activities and broad targeted educational content that speaks to all aspects of the Parkinson’s experience. MJFF aims to harness the power of peer-to-peer interaction in empowering community members to take action and live well with Parkinson’s.

Financial terms:

Latest news:

Is general: Yes